Summary
73
Cubosomes are inverse bicontinuous cubic lyotropic crystalline nanoparticles that can be 74 loaded with poorly water-soluble drugs in their three-dimensional cubic phases, leading to 75 pronounced increases in the solubility, stability and bioavailability of these drugs.
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76
Cubosomes can be prepared using nontoxic, biocompatible and biodegradable ingredients, Wako Chemical Industries, Ltd (Osaka, Japan). All of the other reagents used in this study
107
were purchased as the highest grades available from commercial sources.
108
Preparation of Cubosomes
109
The SPI-and NI-loaded cubosomes were prepared using a high-pressure homogenization 110 technique according to a slightly modified version of a previously published method.
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111
Briefly, 900 mg of monoolein, 40 mg of SPI/NI and 100 mg of pluronic F-127 were added to 112 a beaker containing 20 mL of chloroform, and the resulting mixture was manually agitated to 113
give a solution. All of the processes to prepare NI-loaded cubosomes were conducted in were placed in a polyimide tube of 1 mm in diameter. The distance between the sample and 134 the detector was set to 510 mm and the system was calibrated using powdered silver behenate.
135
The temperature and exposure time were adjusted to 25 °C and 5 min, respectively. were set at 40 °C and 236 nm, respectively. All of the samples were quantified in triplicate.
154
Quantitative Evaluation of SPI and NI by LC-MS/MS
155
The SPI concentration was determined by LC-MS/MS using an API-3000 system (Agilent the precursor ion and the product ion of CAN, respectively.
169
The NI concentration was determined by LC-MS/MS analysis as above using a Cadenza were performed in triplicate.
179
Drug Encapsulation Efficiency
180
The cubosome preparations consisted of a mixture of encapsulated and free drug (un- The SPI-and NI-loaded cubosomes were stored at 20 °C in the dark prior to use and their 194 mean particle size and PDI values were measured at 0, 1, 2, 3 and 4 weeks using the methods 195 described above.
196
In Vitro Release of SPI and NI from Cubosomes
197
The in vitro release characteristics of the monoolein cubosome samples were examined filter. Finally, the concentration of drug released into the release medium was determined by 210 HPLC as described above. These experiments were conducted in triplicate. NI-loaded and blank cubosomes were less than 0.3, indicating that they were monodispersed.
246
The SAXS patterns and lattice parameters of the SPI-loaded, NI-loaded and blank 247 cubosomes are shown in Fig. 1 and 
255
The apparent solubilities of SPI and NI increased when they were encapsulated in the 256 monoolein cubosomes, as shown in Table 1 . The encapsulation of SPI in the monoolein 257 cubosomes led to a 6-fold increase in its solubility (28 µg/mL in water at 25 °C).
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258
Furthermore, the solubility of NI increased around 9-fold (20 µg/mL in water at 25 °C) 
272
Stability Study
273
The mean particle size and PDI values of the SPI-and NI-loaded cubosomes remained 274 largely unchanged for up to 4 weeks at 20 °C (Fig. 2) . The results of the stability study with the rest of the drug molecules remaining unchanged within the nanoparticles.
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299
In Vivo Pharmacokinetic Study
300
The oral bioavailabilities of the SPI-and NI-loaded cubosomes were investigated in rats
301
and the results were compared with those of the corresponding pure drug dispersions. The 302 pharmacokinetic parameters of these materials are shown in Table 3 . The concentration of 303 CAN, a major metabolite of SPI and NI, was determined at different time intervals in all four 304 of these systems, and the results were plotted against time (Fig. 4) . These results therefore 
315
Based on these results, we speculated that several factors could be responsible for the 316 observed increases in the absorption characteristics of these two drugs.
317
Several mechanisms, acting in isolation or in combination, can lead to an increase in the 
